Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis
Clinical study of anti-tumor necrosis factor therapy in patients with Takayasu arteritis.

This study is single arm (anti Tumor necrosis factor therapy only) clinical trial. Enrolled patients will be 11
Takayasu's Arteritis
DRUG: remicade (anti tumor necrosis factor inhibitor)
remission induction at 30 weeks, 30 weeks
Clinical study of anti-tumor necrosis factor therapy in patients with Takayasu arteritis.

This study is single arm (anti Tumor necrosis factor therapy only) clinical trial. Enrolled patients will be 11 patients with active takayasu's arteritis